Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Escherichia coli | Beta-lactamase TEM | Starlite/ChEMBL | References |
Bacteroides fragilis | Beta-lactamase type II | Starlite/ChEMBL | References |
Enterobacter cloacae | Beta-lactamase | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target/s | Ortholog Group |
---|---|---|---|
Mycobacterium tuberculosis | Possible penicillin-binding protein | Get druggable targets OG5_149948 | All targets in OG5_149948 |
Mycobacterium ulcerans | class a beta-lactamase, BlaC | Get druggable targets OG5_143180 | All targets in OG5_143180 |
Mycobacterium tuberculosis | Class a beta-lactamase BlaC | Get druggable targets OG5_143180 | All targets in OG5_143180 |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Onchocerca volvulus | Beta-lactamase type II | 249 aa | 253 aa | 20.6 % | |
Mycobacterium tuberculosis | Nicotinic acid phosphoribosyltransferase PncB2 | Beta-lactamase type II | 249 aa | 214 aa | 19.6 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus multilocularis | gamma secretase subunit aph 1 | 0.355 | 1 | 0.5 |
Mycobacterium ulcerans | class a beta-lactamase, BlaC | 0.016 | 0 | 0.5 |
Mycobacterium tuberculosis | Possible penicillin-binding protein | 0.0278 | 0.0347 | 1 |
Trypanosoma cruzi | Aph-1 protein, putative | 0.1383 | 0.3608 | 0.5 |
Trypanosoma brucei | Aph-1 protein, putative | 0.1383 | 0.3608 | 0.5 |
Trypanosoma cruzi | Aph-1 protein, putative | 0.1383 | 0.3608 | 0.5 |
Echinococcus granulosus | gamma secretase subunit aph 1 | 0.355 | 1 | 0.5 |
Loa Loa (eye worm) | gamma-secretase subunit aph-1 | 0.355 | 1 | 0.5 |
Schistosoma mansoni | gamma-secretase subunit aph-1 | 0.355 | 1 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 2 nM | Inhibition of Enterobacter cloacae AmpC | ChEMBL. | 15588091 |
IC50 (binding) | = 2 nM | Inhibition of Enterobacter cloacae AmpC | ChEMBL. | 15588091 |
IC50 (binding) | = 8 nM | Inhibition of Escherichia coli TEM1 | ChEMBL. | 15588091 |
IC50 (binding) | = 8 nM | Inhibition of Escherichia coli TEM1 | ChEMBL. | 15588091 |
IC50 (binding) | = 370 nM | Inhibition of Bacteroides fragilis CcrA | ChEMBL. | 15588091 |
IC50 (binding) | = 370 nM | Inhibition of Bacteroides fragilis CcrA | ChEMBL. | 15588091 |
MIC (functional) | < 0.06 ug ml-1 | Antimicrobial activity against Escherichia coli GC 2804 expressing Imp in presence of 4 ug/mL piperacillin | ChEMBL. | 15588091 |
MIC (functional) | < 0.06 ug ml-1 | Antimicrobial activity against Staphylococcus aureus GC 2216 in presence of 4 ug/mL piperacillin | ChEMBL. | 15588091 |
MIC (functional) | < 0.06 ug ml-1 | Antimicrobial activity against Escherichia coli GC 2804 expressing Imp in presence of 4 ug/mL piperacillin | ChEMBL. | 15588091 |
MIC (functional) | = 2 ug ml-1 | Antimicrobial activity against Escherichia coli GC 2844 in presence of 4 ug/mL piperacillin | ChEMBL. | 15588091 |
MIC (functional) | = 2 ug ml-1 | Antimicrobial activity against Escherichia coli GC 2920 expressing IRT2 in presence of 4 ug/mL piperacillin | ChEMBL. | 15588091 |
MIC (functional) | = 2 ug ml-1 | Antimicrobial activity against Serratia marcescens GC 1781 expressing Sme1 and AmpC in presence of 4 ug/mL piperacillin | ChEMBL. | 15588091 |
MIC (functional) | = 2 ug ml-1 | Antimicrobial activity against Serratia marcescens GC 4142 expressing AmpC in presence of 4 ug/mL piperacillin | ChEMBL. | 15588091 |
MIC (functional) | = 2 ug ml-1 | Antimicrobial activity against Escherichia coli GC 2203 in presence of 4 ug/mL piperacillin | ChEMBL. | 15588091 |
MIC (functional) | = 2 ug ml-1 | Antimicrobial activity against Escherichia coli GC 2844 in presence of 4 ug/mL piperacillin | ChEMBL. | 15588091 |
MIC (functional) | = 2 ug ml-1 | Antimicrobial activity against Escherichia coli GC 2920 expressing IRT2 in presence of 4 ug/mL piperacillin | ChEMBL. | 15588091 |
MIC (functional) | = 2 ug ml-1 | Antimicrobial activity against Escherichia coli GC 2203 in presence of 4 ug/mL piperacillin | ChEMBL. | 15588091 |
MIC (functional) | = 4 ug ml-1 | Antimicrobial activity against Pseudomonas aeruginosa GC 1764 expressing AmpC in presence of 4 ug/mL piperacillin | ChEMBL. | 15588091 |
MIC (functional) | = 8 ug ml-1 | Antimicrobial activity against Escherichia coli GC 2847 expressing TEM1 in presence of 4 ug/mL piperacillin | ChEMBL. | 15588091 |
MIC (functional) | = 8 ug ml-1 | Antimicrobial activity against Enterobacter cloacae GC 2071 expressing Imi1 and AmpC in presence of 4 ug/mL piperacillin | ChEMBL. | 15588091 |
MIC (functional) | = 8 ug ml-1 | Antimicrobial activity against Escherichia coli GC 2847 expressing TEM1 in presence of 4 ug/mL piperacillin | ChEMBL. | 15588091 |
MIC (functional) | = 16 ug ml-1 | Antimicrobial activity against Escherichia coli GC 2252 expressing IRT2 in presence of 4 ug/mL piperacillin | ChEMBL. | 15588091 |
MIC (functional) | = 16 ug ml-1 | Antimicrobial activity against Enterobacter cloacae GC 1475 expressing P99 in presence of 4 ug/mL piperacillin | ChEMBL. | 15588091 |
MIC (functional) | = 16 ug ml-1 | Antimicrobial activity against Klebsiella pneumoniae GC 2825 in presence of 4 ug/mL piperacillin | ChEMBL. | 15588091 |
MIC (functional) | = 16 ug ml-1 | Antimicrobial activity against Escherichia coli GC 2252 expressing IRT2 in presence of 4 ug/mL piperacillin | ChEMBL. | 15588091 |
MIC (functional) | = 32 ug ml-1 | Antimicrobial activity against Enterobacter cloacae GC 1477 expressing AmpC in presence of 4 ug/mL piperacillin | ChEMBL. | 15588091 |
MIC (functional) | > 64 ug ml-1 | Antimicrobial activity against Escherichia coli GC 2805 expressing CcrA in presence of 4 ug/mL piperacillin | ChEMBL. | 15588091 |
MIC (functional) | > 64 ug ml-1 | Antimicrobial activity against Escherichia coli GC 2805 expressing CcrA in presence of 4 ug/mL piperacillin | ChEMBL. | 15588091 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.